02.15.18
Need help with influencer marketing? The Interactive Advertising Bureau has published a new guide that publishers and marketers can use to maximize their influencer marketing programs.
For the Federal Trade Commission (FTC), 2018 looks to be a year of transition, with President Donald J. Trump officially submitting four commissioner nominations for Senate approval.
Demonstrating the power of punctuation, actor James Woods dodged a Twitter defamation suit after a federal court judge found that his use of a question mark meant his tweet was not a false statement of fact and merely invited the reader to reach his or her own conclusion.
Claims touting an allergy medication as “smart” or “wise” conferred a clinically meaningful benefit as compared to a competitor’s product and should be discontinued, the National Advertising Division (NAD) recently recommended.
02.08.18
Tipping its hat to the Enforcement Policy Statement on U.S. Origin Claims, the Federal Trade Commission (FTC) filed suit against Bollman Hat Co. and a subsidiary for deceiving consumers with “Made in USA” claims for its hats and third-party products.
Marketers of opioid cessation products received warning letters from the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC), cautioning them about unproven claims for the treatment of opioid addiction and withdrawal.
Applying last year’s U.S. Supreme Court decision in Bristol-Myers Squibb Co. v. Superior Court of California, an Illinois federal court dismissed nationwide class claims against NBTY, Inc., for lack of jurisdiction.
Once was enough, the U.S. Supreme Court signaled when it denied a writ of certiorari filed by Spokeo, Inc., seeking further clarification on Article III standing.
02.01.18
Citing a link between advertisements and an unrealistic body image, CVS announced that the national pharmacy chain will no longer use touched-up images in advertisements for its beauty products.
After StubHub.com declined to comply with the National Advertising Division’s recommendations with regard to its pricing claims, the self-regulatory body referred the issue to the Federal Trade Commission (FTC) for review.